10x Genomics Quarterly Cash Flow Statement
NASDAQ: TXGIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
10x Genomics free cash flow
In the quarter ended Jun 30, 2026, 10x Genomics generated $17.0 million of operating cash flow and spent $1.6 million on capital expenditures. That left free cash flow of $15.4 million, a free-cash-flow margin of 10.2% of revenue. Free cash flow was down 4.6% from the prior year's $16.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
10x Genomics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -17.93M | -13.47M | -16.25M | -27.47M | 34.54M | -34.36M | -49.03M | -35.75M | -37.90M | -59.95M | -48.95M | -92.99M |
| Net Income growth (YoY) | -151.92% | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 9.66M | 9.96M | 10.06M | 10.30M | 7.82M | 8.02M | 8.75M | 8.96M | 8.97M | 9.19M | 9.72M | 9.37M |
| Stock-Based Compensation | 25.62M | 22.64M | 25.22M | 25.26M | 27.56M | 31.08M | 32.54M | 33.59M | 38.49M | 36.13M | 38.92M | 40.23M |
| Change in Working Capital | -16.01M | 15.21M | -3.27M | 13.38M | 14.97M | 43.50M | -4.32M | 10.35M | -2.59M | 20.50M | -2.66M | 3.81M |
| Operating Cash Flow | 16.97M | 26.12M | 40.78M | 43.21M | 17.71M | 34.35M | -6.75M | 21.64M | 7.50M | -15.72M | 25.76M | -25.30M |
| Capital Expenditures | -1.59M | -1.60M | -1.78M | -687.00K | -1.58M | -1.89M | -2.72M | -3.89M | -2.88M | -2.91M | -3.45M | -15.24M |
| Investing Cash Flow | -7.74M | -1.31M | -1.80M | -8.80M | -939.00K | -1.89M | -51.59M | -3.62M | 11.95M | 10.63M | 13.10M | 4.90M |
| Financing Cash Flow | 3.02M | -8.42M | 2.24M | 617.00K | 3.52M | 422.00K | 4.52M | 156.00K | 4.60M | 1.64M | 5.61M | 4.37M |
| Net Change in Cash | 12.23M | 16.32M | 41.26M | 35.00M | 20.65M | 32.99M | -54.09M | 18.34M | 24.04M | -3.50M | 44.55M | -16.11M |
| Free Cash Flow | 15.39M | 24.52M | 39.00M | 42.53M | 16.13M | 32.46M | -9.46M | 17.75M | 4.62M | -18.64M | 22.31M | -40.54M |
This table shows 12 quarterly periods of 10x Genomics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TXG's reporting calendar. What is a cash flow statement?